Literature DB >> 22205430

Cysteamine therapy: a treatment for cystinosis, not a cure.

Stephanie Cherqui.   

Abstract

Cystinosis as a clinical entity is a progressive dysfunction of multiple organs caused by the accumulation of cystine in the tissues, leading, for example, to end-stage renal failure, diabetes, hypothyroidism, myopathy, and central nervous system deterioration. Brodin-Sartorius and colleagues present a long-term study on the impact of cysteamine therapy on these complications. The data show that cysteamine improves the outcome and complications of cystinosis but does not prevent them.

Entities:  

Mesh:

Year:  2012        PMID: 22205430      PMCID: PMC3386783          DOI: 10.1038/ki.2011.301

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

1.  Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo.

Authors:  J G Thoene; R G Oshima; J C Crawhall; D L Olson; J A Schneider
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

2.  Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter.

Authors:  V Kalatzis; S Cherqui; C Antignac; B Gasnier
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

3.  Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.

Authors:  Albane Brodin-Sartorius; Marie-Josèphe Tête; Patrick Niaudet; Corinne Antignac; Geneviève Guest; Chris Ottolenghi; Marina Charbit; Dominique Moyse; Christophe Legendre; Philippe Lesavre; Pierre Cochat; Aude Servais
Journal:  Kidney Int       Date:  2011-09-07       Impact factor: 10.612

4.  Long-term treatment of cystinosis in children with twice-daily cysteamine.

Authors:  Ranjan Dohil; Jon A Gangoiti; Betty L Cabrera; Meredith Fidler; Jerry A Schneider; Bruce A Barshop
Journal:  J Pediatr       Date:  2010-02-06       Impact factor: 4.406

5.  Cysteamine therapy for children with nephropathic cystinosis.

Authors:  W A Gahl; G F Reed; J G Thoene; J D Schulman; W B Rizzo; A J Jonas; D W Denman; J J Schlesselman; B J Corden; J A Schneider
Journal:  N Engl J Med       Date:  1987-04-16       Impact factor: 91.245

Review 6.  Nephropathic cystinosis: late complications of a multisystemic disease.

Authors:  Galina Nesterova; William Gahl
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

7.  Parenchymal organ cystine depletion with long-term cysteamine therapy.

Authors:  W A Gahl; L Charnas; T C Markello; I Bernardini; K G Ishak; M C Dalakas
Journal:  Biochem Med Metab Biol       Date:  1992-12

8.  Renal phenotype of the cystinosis mouse model is dependent upon genetic background.

Authors:  Nathalie Nevo; Marie Chol; Anne Bailleux; Vasiliki Kalatzis; Ludivine Morisset; Olivier Devuyst; Marie-Claire Gubler; Corinne Antignac
Journal:  Nephrol Dial Transplant       Date:  2009-10-21       Impact factor: 5.992

9.  Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy.

Authors:  William A Gahl; Joan Z Balog; Robert Kleta
Journal:  Ann Intern Med       Date:  2007-08-21       Impact factor: 25.391

10.  Successful treatment of the murine model of cystinosis using bone marrow cell transplantation.

Authors:  Kimberly Syres; Frank Harrison; Matthew Tadlock; James V Jester; Jennifer Simpson; Subhojit Roy; Daniel R Salomon; Stephanie Cherqui
Journal:  Blood       Date:  2009-06-08       Impact factor: 22.113

View more
  35 in total

Review 1.  Regulation of TFEB activity and its potential as a therapeutic target against kidney diseases.

Authors:  Weihuang Zhang; Xiaoyu Li; Shujun Wang; Yanse Chen; Huafeng Liu
Journal:  Cell Death Discov       Date:  2020-05-01

Review 2.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

3.  Interaction between galectin-3 and cystinosin uncovers a pathogenic role of inflammation in kidney involvement of cystinosis.

Authors:  Tatiana Lobry; Roy Miller; Nathalie Nevo; Celine J Rocca; Jinzhong Zhang; Sergio D Catz; Fiona Moore; Lucie Thomas; Daniel Pouly; Anne Bailleux; Ida Chiara Guerrera; Marie-Claire Gubler; Wai W Cheung; Robert H Mak; Tristan Montier; Corinne Antignac; Stephanie Cherqui
Journal:  Kidney Int       Date:  2019-03-06       Impact factor: 10.612

4.  Cross-regulation of defective endolysosome trafficking and enhanced autophagy through TFEB in UNC13D deficiency.

Authors:  Jinzhong Zhang; Jing He; Jennifer L Johnson; Gennaro Napolitano; Mahalakshmi Ramadass; Farhana Rahman; Sergio D Catz
Journal:  Autophagy       Date:  2019-04-05       Impact factor: 16.016

5.  Cell-Based Phenotypic Drug Screening Identifies Luteolin as Candidate Therapeutic for Nephropathic Cystinosis.

Authors:  Ester De Leo; Mohamed A Elmonem; Sante Princiero Berlingerio; Marine Berquez; Beatrice Paola Festa; Roberto Raso; Francesco Bellomo; Tobias Starborg; Manoe Jacoba Janssen; Zeinab Abbaszadeh; Sara Cairoli; Bianca Maria Goffredo; Rosalinde Masereeuw; Olivier Devuyst; Martin Lowe; Elena Levtchenko; Alessandro Luciani; Francesco Emma; Laura Rita Rega
Journal:  J Am Soc Nephrol       Date:  2020-06-05       Impact factor: 10.121

Review 6.  [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].

Authors:  Jessica Kaufeld; Lutz T Weber; Christine Kurschat; Sima Canaan-Kuehl; Eva Brand; Jun Oh; Lars Pape
Journal:  Internist (Berl)       Date:  2018-08       Impact factor: 0.743

Review 7.  Potential use of stem cells as a therapy for cystinosis.

Authors:  Celine J Rocca; Stephanie Cherqui
Journal:  Pediatr Nephrol       Date:  2018-05-22       Impact factor: 3.714

8.  Cystinosin, the small GTPase Rab11, and the Rab7 effector RILP regulate intracellular trafficking of the chaperone-mediated autophagy receptor LAMP2A.

Authors:  Jinzhong Zhang; Jennifer L Johnson; Jing He; Gennaro Napolitano; Mahalakshmi Ramadass; Celine Rocca; William B Kiosses; Cecilia Bucci; Qisheng Xin; Evripidis Gavathiotis; Ana María Cuervo; Stephanie Cherqui; Sergio D Catz
Journal:  J Biol Chem       Date:  2017-05-02       Impact factor: 5.157

9.  Protection of Cystinotic Mice by Kidney-Specific Megalin Ablation Supports an Endocytosis-Based Mechanism for Nephropathic Cystinosis Progression.

Authors:  Virginie Janssens; Héloïse P Gaide Chevronnay; Sandrine Marie; Marie-Françoise Vincent; Patrick Van Der Smissen; Nathalie Nevo; Seppo Vainio; Rikke Nielsen; Erik I Christensen; François Jouret; Corinne Antignac; Christophe E Pierreux; Pierre J Courtoy
Journal:  J Am Soc Nephrol       Date:  2019-09-23       Impact factor: 10.121

Review 10.  Is genetic rescue of cystinosis an achievable treatment goal?

Authors:  Stephanie Cherqui
Journal:  Nephrol Dial Transplant       Date:  2013-07-16       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.